PRINCETON, N.J. and SUZHOU, China, March 27, 2025 -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announced that it will debut the preclinical data of a novel FGFR2b-targeting ADC as poster presentation at the AACR Annual Meeting to be held in Chicago, USA, from April 25-30, 2025. This ADC, conjugated with a topoisomerase I inhibitor payload using glycosyltransferase-mediated site-specific conjugation, demonstrated significantly enhanced anti-tumor activity compared to MMAE-based ADCs in preclinical gastric and colorectal tumor models.

PRINCETON, N.J. and SUZHOU, China, April 26, 2024 -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it is going to present results of cohort G from a phase I/IIa study: first-line Osemitamab (TST001) plus Nivolumab and CAPOX for advanced G/GEJ cancer (TranStar102) at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024 from May 31 to June 4, 2024, in Chicago, IL, U.S..

SUZHOU, China, October 19, 2023 -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it is going to present three posters highlighting study results from ongoing trials related to Osemitamab (TST001) at the 2023 European Society of Medical Oncology (ESMO) Congress including updated efficacy and PK/PD analysis data from the phase 2 study of Osemitamab (TST001)/CAPOX in CLDN18.2 positive first line G/GEJC as well as preclinical data on the combination study of Osemitamab (TST001) with PD1 inhibitor.